Pathkey.AI logo

Pathkey.AI(ASX) PKY

Market CapA$25.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-99%
5 Year-87%
1 Year-24%
1 Month-37%
A$0.02
-5.00%
-0.00Today
Pathkey.AI last closing stock price
MetricPriceDate
Last closeAUD 0.022026-10-14
Pathkey.AI stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.39%AUD 0.022026-10-06
1 month-36.67%AUD 0.032026-09-14
3 month-53.66%AUD 0.042026-07-16
Year to date+18.75%AUD 0.022025-12-31
1 year-24%AUD 0.032025-10-14
3 year-56.82%AUD 0.042023-10-11
5 year-87.33%AUD 0.152021-10-15
Since inception-99.49%AUD 3.922016-01-14

Pathkey.AI Financials at a Glance

Market Cap

A$25.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$75.42K

Net Income (TTM)

-A$5.10M

EPS (TTM)

-A$0.01

P/E Ratio

-2.26

Dividend

A$0.00

Beta (Volatility)

0.04 (Low)

Price

A$0.02

Volume

4,455,769

Open

A$0.02

Previous Close

A$0.02

Daily Range

A$0.02 - A$0.02

52-Week Range

A$0.01 - A$0.08

Estimated Earnings Date

Feb 25, 2026

PKY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pathkey.AI

Pathkey.AI Ltd is an Australian digital health firm that leverages artificial intelligence (AI) to enhance clinical trials and improve patient outcome predictability. The company offers a range of AI-driven solutions tailored for biopharmaceutical companies, MedTech innovators, and healthcare organizations.

Products and Services
  • TrialKey: A platform for simulating and optimizing clinical trial designs
  • TrialGen: An AI-powered tool designed to simplify clinical trial design
  • Consulting services for biopharmaceutical and healthcare organizations
Growth Outlook
  • Projected increase in demand for AI solutions in healthcare
  • Expansion into international markets anticipated by 2026
  • Partnerships with leading healthcare organizations expected to drive growth
Financial Highlights
  • Recent quarterly revenue of AUD 37,215, showing potential for growth
  • Cash and cash equivalents of AUD 3,409,810, providing operational flexibility
  • Current ratio of 7.59 indicates strong short-term financial health
Pathkey.AI Ltd is positioned in the healthcare information services industry, focusing on the integration of AI technologies to streamline clinical trials. The company's flagship products, TrialKey and TrialGen, are designed to enhance the efficiency and success rates of clinical trials, addressing a critical need in the healthcare sector. The growth outlook for Pathkey.AI is promising, driven by the increasing demand for AI solutions in healthcare and anticipated expansion into international markets. Strategic partnerships with established healthcare organizations are expected to further bolster the company's market presence and revenue potential. Financially, Pathkey.AI has demonstrated resilience, with a recent quarterly revenue of AUD 37,215, indicating a foundation for future growth. The company maintains a robust cash position of AUD 3,409,810, which supports ongoing operations and development initiatives. Additionally, a current ratio of 7.59 reflects strong short-term financial health, positioning the company well to navigate future challenges and capitalize on emerging opportunities in the digital health landscape.
AI Generated • Oct 8, 2026

Industry

Software

CEO

Andrew Farnsworth

Website

pathkey.ai

Headquarters

Sydney, NSW 2000, AU

PKY Financials

Key Financial Metrics (TTM)

Gross Margin

-5265.70%

Operating Margin

-8103.97%

Net Income Margin

-7668.54%

Return on Equity

-18.10%

Return on Capital

-9.69%

Return on Assets

-9.06%

Earnings Yield

-44.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$25.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.35B

Volume

4.46M

Avg. Volume

3.39M

Financials (TTM)

Gross Profit

-A$3.29M

Operating Income

-A$5.53M

EBITDA

-A$5.51M

Operating Cash Flow

-A$2.33M

Capital Expenditure

-A$4.62K

Free Cash Flow

-A$2.34M

Cash & ST Invst.

A$3.41M

Total Debt

A$0.00

Pathkey.AI Performance Analysis

Pathkey.AI annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 617,907-31.5%
20242024-06-30AUD 397,637-35.6%
20252025-06-30AUD 27,783-93.0%
20262026-06-30AUD 47,63271.4%
Pathkey.AI sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-72.6%
Q42025-06-30-134.1%
Q22025-12-31172.5%
Q42026-06-30257.3%
Pathkey.AI annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.02-43.6%
20242024-06-30AUD -0.02-11.3%
20252025-06-30AUD -0.01-58.4%
20262026-06-30AUD -0.0116.7%
Pathkey.AI sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3163.3%
Q42025-06-3020.0%
Q22025-12-3128.1%
Q42026-06-30-160.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$37.22K

-75.8%

Gross Profit

-A$2.51M

-167.7%

Gross Margin

-67.40%

N/A

Market Cap

A$25.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.14M

N/A

Employees

5

N/A

Net Income

-A$2.98M

-60.5%

EBITDA

-A$2.98M

-63.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.41M

+810.1%

Total Debt

A$0.00

N/A

Accounts Receivable

A$87.59K

+1035.4%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-9.06%

N/A

Return on Invested Capital

-9.69%

N/A

Free Cash Flow

-A$592.58K

+60.3%

Operating Cash Flow

-A$592.58K

+59.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GTG.AXGenetic Technologies Limited
A$0.04+0.00%
CGB.AXCann Global Limited
A$0.02+0.00%
UBI.AXUniversal Biosensors, Inc.
A$0.01+0.00%
VTI.AXVisioneering Technologies, Inc.
A$0.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.08-5.34%
CRWVCoreWeave
$65.14-16.28%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.26+12.94%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.17-12.86%

Questions About PKY

What is the current price of Pathkey.AI?

Pathkey.AI is trading at A$0.02 per share.

What is the 52-week range for Pathkey.AI?

Over the past 52 weeks, Pathkey.AI has traded between A$0.01 and A$0.08.

How much debt does Pathkey.AI have?

As of the most recent reporting period, Pathkey.AI reported total debt of A$0.00.

How much cash does Pathkey.AI have on hand?

Pathkey.AI reported A$3.41M in cash and cash equivalents in its most recent financial results.

What is Pathkey.AI’s dividend yield?

Pathkey.AI does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.